A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C
Latest Information Update: 01 Jan 2022
At a glance
- Drugs Sorafenib (Primary) ; Yttrium-90
- Indications Liver cancer
- Focus Therapeutic Use
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 07 Aug 2020 Planned primary completion date changed from 30 Sep 2020 to 30 Sep 2021.
- 14 Nov 2019 Planned End Date changed from 30 Sep 2020 to 30 Sep 2021.